AU5895496A - Phenyldihydrobenzofurans - Google Patents

Phenyldihydrobenzofurans

Info

Publication number
AU5895496A
AU5895496A AU58954/96A AU5895496A AU5895496A AU 5895496 A AU5895496 A AU 5895496A AU 58954/96 A AU58954/96 A AU 58954/96A AU 5895496 A AU5895496 A AU 5895496A AU 5895496 A AU5895496 A AU 5895496A
Authority
AU
Australia
Prior art keywords
pct
date nov
sec
pub
pct pub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU58954/96A
Other versions
AU698028B2 (en
Inventor
Hermann Amschler
Thomas Bar
Rolf Beume
Hildegard Boss
Dieter Flockerzi
Beate Gutterer
Dietrich Hafner
Armin Hatzelmann
Hans-Peter Kley
Thomas Martin
Ulrich Thibaut
Wolf-Rudiger Ulrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Publication of AU5895496A publication Critical patent/AU5895496A/en
Application granted granted Critical
Publication of AU698028B2 publication Critical patent/AU698028B2/en
Assigned to ALTANA PHARMA AG reassignment ALTANA PHARMA AG Request to Amend Deed and Register Assignors: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7

Abstract

PCT No. PCT/EP96/02031 Sec. 371 Date Nov. 18, 1997 Sec. 102(e) Date Nov. 18, 1997 PCT Filed May 11, 1996 PCT Pub. No. WO96/36625 PCT Pub. Date Nov. 21, 1996Compounds of formula I are selective cyclic nucleotide phosphodiesterase (PDE) inhibitors (namely of type IV). They and pharmaceutical compositions in which they are active ingredients are useful as bronchial therapeutics, for elimination of erectile dysfunction and for treatment of disorders, particularly those of inflammatory nature. The compounds are distinguished by low toxicity, good enteral absorption (high bioavailability), a great therapeutic breadth and the absence of significant side effects.
AU58954/96A 1995-05-18 1996-05-11 Phenyldihydrobenzofurans Ceased AU698028B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1472/95 1995-05-18
CH147295 1995-05-18
PCT/EP1996/002031 WO1996036625A1 (en) 1995-05-18 1996-05-11 Phenyl dihydrobenzofuranes

Publications (2)

Publication Number Publication Date
AU5895496A true AU5895496A (en) 1996-11-29
AU698028B2 AU698028B2 (en) 1998-10-22

Family

ID=4211283

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58954/96A Ceased AU698028B2 (en) 1995-05-18 1996-05-11 Phenyldihydrobenzofurans

Country Status (12)

Country Link
US (1) US5902824A (en)
EP (1) EP0828728B1 (en)
JP (1) JPH11505236A (en)
AT (1) ATE231501T1 (en)
AU (1) AU698028B2 (en)
CA (1) CA2221357A1 (en)
CY (1) CY2466B1 (en)
DE (1) DE59610077D1 (en)
DK (1) DK0828728T3 (en)
ES (1) ES2191754T3 (en)
PT (1) PT828728E (en)
WO (1) WO1996036625A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4172817B2 (en) * 1995-05-19 2008-10-29 協和醗酵工業株式会社 Oxygenated heterocyclic compounds
US6514996B2 (en) 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
EP2223920A3 (en) 1996-06-19 2011-09-28 Aventis Pharma Limited Substituted azabicyclic compounds
JP2001505198A (en) * 1996-11-20 2001-04-17 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング Substituted dihydrobenzofurans as PDE inhibitors
US6247016B1 (en) * 1998-08-24 2001-06-12 Lucent Technologies, Inc. Decision tree classifier with integrated building and pruning phases
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
SK287231B6 (en) 1999-08-21 2010-04-07 Nycomed Gmbh Medicament comprising a PDE inhibitor and a beta2 adrenoreceptor agonist
ATE347557T1 (en) * 2000-03-23 2006-12-15 Takeda Pharmaceutical FLUORISOQUINOLINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE
NZ524572A (en) * 2000-09-06 2004-08-27 Tanabe Seiyaku Co Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
JP4179784B2 (en) * 2001-02-15 2008-11-12 田辺三菱製薬株式会社 Orally disintegrating tablets
DE10205274A1 (en) * 2002-02-08 2003-08-21 Boehringer Ingelheim Pharma New drug compositions containing in addition to anticholinergics heterocyclic compounds
SE0202133D0 (en) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
SE0302755D0 (en) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel compounds
SE0303090D0 (en) 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303541D0 (en) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
PE20070182A1 (en) * 2005-07-29 2007-03-06 Wyeth Corp CYANOPYRROL-PHENYL AMIDE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS
PE20070341A1 (en) * 2005-07-29 2007-04-13 Wyeth Corp PIRROL DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド 5HT receptor-mediated neurogenesis
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605923A (en) * 1992-04-02 1997-02-25 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
MX9301943A (en) * 1992-04-02 1994-08-31 Smithkline Beecham Corp COMPOUNDS.
US5602173A (en) * 1992-04-02 1997-02-11 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
DK0652868T3 (en) * 1992-07-28 2005-02-14 Aventis Pharma Ltd Inhibitors of c-AMP phosphodiesterase
JP4172817B2 (en) * 1995-05-19 2008-10-29 協和醗酵工業株式会社 Oxygenated heterocyclic compounds

Also Published As

Publication number Publication date
ES2191754T3 (en) 2003-09-16
AU698028B2 (en) 1998-10-22
WO1996036625A1 (en) 1996-11-21
CY2466B1 (en) 2005-06-03
US5902824A (en) 1999-05-11
EP0828728A1 (en) 1998-03-18
PT828728E (en) 2003-06-30
JPH11505236A (en) 1999-05-18
DK0828728T3 (en) 2003-05-19
EP0828728B1 (en) 2003-01-22
CA2221357A1 (en) 1996-11-21
DE59610077D1 (en) 2003-02-27
ATE231501T1 (en) 2003-02-15

Similar Documents

Publication Publication Date Title
AU5895496A (en) Phenyldihydrobenzofurans
AU5764496A (en) Cyclohexyl dihydrobenzofuranes
MXPA04012965A (en) Viral inhibitors.
MY132106A (en) New pyridazin-3(2h)-one derivatives
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
MXPA05002871A (en) Benzodiazepine derivatives and pharmaceutical compositions containing them.
AU2003215753A1 (en) Imidazopyridine derivatives as kinase inhibitors
BG103969A (en) C-4"-substituted macrolide derivatives
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
MY119181A (en) Aryl pyrimidine derivatives
AU2003297048A8 (en) Cyclohexyl compounds as ccr5 antagonists
RS101304A (en) indole,azaindole and related heterocyclic 4-alkenyl piperadine amides
AU2003296992A1 (en) Pyrrolidine and azetidine compounds as ccr5 antagonists
AU2003300911A1 (en) Heterocyclic compounds as ccr5 antagonists
EA200000355A2 (en) INDUSTRIAL PRODUCTS
MXPA04010307A (en) 5-oxo and 5-thio derivatives of 5h-indeno'1,2-bipyridine with adenosine a2a receptor binding and phosphodiesterase inhibiting activity for the treatment of neurodegenerative disorders and inflammation related diseases.
WO2001080860A3 (en) Daily treatment for erectile dysfunction using a pde5 inhibitor
IL125628A0 (en) Benzo[c] quinolizine derivatives their preparation and use as 5alpha-reductase inhibitors
TW200505916A (en) 7-azaindoles and the use thereof as therapeutic agents
TW200503693A (en) 4-, 6- or 7-hydroxyindoles with n-oxide groups and the use thereof as therapeutic agents
CA2239053A1 (en) Diphenyl pyridyl ethane derivatives as pde iv inhibitors
GEP20094596B (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction
YU87302A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ALTANA PHARMA AG

Free format text: FORMER NAME WAS: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH